AbbVie adds biologic production capability to Singapore facility
AbbVie has expanded the operational capability of its facility located at the Tuas Biomedical Park in Singapore with the addition of a biologics manufacturing facility. The move means the plant will now add the production of biological drugs to its repertoire in addition to small molecule active pharmaceutical ingredients (APIs).
The plant is the 13th site within the company’s global manufacturing network which spans across the US, Europe and Puerto Rico, and is the only one of its kind within the network with the capability to produce both biologics and APIs. AbbVie employs around 400 workers in Singapore, around 250 of which serve at the manufacturing plant.
Singapore’s Minister for Trade and Industry, S Iswaran, was present at the opening ceremony, where he said the facility expansion came at an “opportune moment” to meet the increasing demands of ageing populations and technological advancement.
“While these shifts will disrupt existing business models, they also present significant new opportunities,” he said.
According to Iswaran, the country’s government is committed to investing S$4 billion in health and biomedical sciences in addition to a further S$3.2 billion in advanced manufacturing and engineering as part of the Research Innovation and Enterprise (RIE) 2020 plan, a programme jointly developed by Workforce Singapore and the Singapore Economic Development Board.
“A strategic goal of RIE 2020 is to strengthen linkages between public research performers and private enterprises to create greater value from our investments in R&D,” Iswaran noted.
Over 350 people have benefitted from the programme since its inception in 2014.
AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a …
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …